Akebia Therapeutics, Inc. - Common Stock (AKBA)

Historical Holders from Q1 2014 to Q2 2025

Symbol
AKBA on Nasdaq
CUSIP
00972D105
Type / Class
Equity / Common Stock
Shares outstanding
236M
All holders as of June 30, 2025
Q2 2025
Total 13F shares, excl. options
108M
Holdings value
$394M
% of all portfolios
0.001%
Grand Portfolio weight change
+0%
Number of holders
157
Number of buys
109
Number of sells
-41
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akebia Therapeutics, Inc. - Common Stock (AKBA)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.1% $28.5M 15.1M BlackRock, Inc. Mar 31, 2025
VANGUARD GROUP INC 5.37% $23.8M 12.7M The Vanguard Group Mar 31, 2025
Satter Muneer A 2.6% $10.8M 5.75M Satter Muneer A Dec 31, 2024

Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q2 108M $394M +$56.5M $3.64 157
2025 Q1 95.2M $183M +$63.4M $1.92 142
2024 Q4 67.8M $129M +$16.4M $1.90 120
2024 Q3 59.4M $78.4M +$883K $1.32 115
2024 Q2 56.3M $57.4M -$2.48M $1.02 101
2024 Q1 57M $104M +$1.82M $1.83 113
2023 Q4 54.6M $67.8M +$4.18M $1.24 82
2023 Q3 50.8M $57.9M +$685K $1.14 71
2023 Q2 50.2M $46M -$1.39M $0.92 75
2023 Q1 49.1M $27.5M +$24.3K $0.56 60
2022 Q4 49.3M $28.5M +$1.76M $0.58 68
2022 Q3 51.1M $16.2M -$1.54M $0.32 71
2022 Q2 52.7M $18.6M -$7.47M $0.35 77
2022 Q1 80.1M $57.5M -$32.8M $0.72 111
2021 Q4 94.9M $215M -$4.44M $2.26 122
2021 Q3 91.5M $263M -$28.7M $2.88 113
2021 Q2 101M $381M +$8.31M $3.79 130
2021 Q1 98.5M $333M -$7.6M $3.38 130
2020 Q4 98.3M $275M -$4.62M $2.80 126
2020 Q3 97.4M $244M -$415M $2.51 150
2020 Q2 111M $1.51B +$246M $13.58 180
2020 Q1 81.4M $617M +$70.5M $7.58 142
2019 Q4 72.4M $458M -$7.38M $6.32 141
2019 Q3 83.3M $327M -$6.48M $3.92 138
2019 Q2 86.4M $418M -$1.55M $4.84 143
2019 Q1 75.7M $620M +$32.9M $8.19 158
2018 Q4 71.2M $393M +$199M $5.53 148
2018 Q3 40.8M $360M -$21.3M $8.83 123
2018 Q2 42.4M $423M -$3.99M $9.98 135
2018 Q1 42.8M $409M +$77.9M $9.53 143
2017 Q4 33.4M $497M +$18.7M $14.87 125
2017 Q3 29.9M $588M +$66.4M $19.67 115
2017 Q2 27.3M $392M +$96.2M $14.37 113
2017 Q1 20.8M $191M +$23.1M $9.20 84
2016 Q4 20.2M $210M +$3.87M $10.41 89
2016 Q3 19.2M $174M -$251K $9.05 81
2016 Q2 19.6M $147M -$12.7M $7.48 90
2016 Q1 21.1M $191M +$34.3M $9.01 90
2015 Q4 15.8M $204M +$34.8M $12.92 86
2015 Q3 13.6M $131M +$22.2M $9.66 79
2015 Q2 10.6M $109M +$58.5M $10.29 67
2015 Q1 6.12M $68M -$4.5M $11.11 56
2014 Q4 6.52M $75.9M -$6.54M $11.64 53
2014 Q3 5.6M $124M +$8.04M $22.13 48
2014 Q2 6.58M $183M +$181M $27.79 48
2014 Q1 104K $2.03M +$2.03M $19.56 3